KURA ONCOLOGY, INC. Long-Term Debt, Maturity, Year One
KURA ONCOLOGY, INC. (KURA) had Long-Term Debt, Maturity, Year One of $2.33 million as of 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths · last filed 2025-02-28
- 2024-12-31: Long-Term Debt, Maturity, Year One $2.33M.
- 2020-12-31: Long-Term Debt, Maturity, Year One $3.33M.
- 2019-12-31: Long-Term Debt, Maturity, Year One $669.00K.
- 2018-12-31: Long-Term Debt, Maturity, Year One $436.00K.
| Period end | Long-Term Debt, Maturity, Year One |
|---|---|
| 2024-12-31 | $2.33M 10-K · filed 2025-02-28 |
| 2020-12-31 | $3.33M 10-K · filed 2021-02-24 |
| 2019-12-31 | $669.00K 10-K · filed 2020-02-25 |
| 2018-12-31 | $436.00K 10-K · filed 2019-03-05 |
| 2017-12-31 | $2.38M 10-K · filed 2018-03-12 |
| 2016-12-31 | $607.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |